Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS⢠technology platform allows us to identify immunotherapy targets based on each personâs tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called âinhibitoryâ antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. Source
No articles found.
CARROT is a fitness app that rewards users financially for walking and meeting per...
CARROT is a fitness app that rewards users fina...
BIOLASE, Inc. is a medical device company and global market leader in the manufact...
BIOLASE, Inc. is a medical device company and g...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
Emerald Health Pharmaceuticals (EHP) combines decades of life science and drug dev...
Emerald Health Pharmaceuticals (EHP) combines d...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.